Abstract
The onset of X inactivation coincides with accumulation of Xist RNA along the future inactive X chromosome. A recent hypothesis proposed that accumulation is initiated by a promoter switch within Xist. In this hypothesis, an upstream promoter (P0) produces an unstable transcript, while the known downstream promoter (P1) produces a stable RNA. To test this hypothesis, we examined expression and half-life of Xist RNA produced from an Xist transgene lacking P0 but retaining P1. We confirm the previous finding that P0 is dispensable for Xist expression in undifferentiated cells and that P1 can be used in both undifferentiated and differentiated cells. Herein, we show that Xist RNA initiated at P1 is unstable and does not accumulate. Further analysis indicates that the transcriptional boundary at P0 does not represent the 5′ end of a distinct Xist isoform. Instead, P0 is an artifact of cross-amplification caused by a pseudogene of the highly expressed ribosomal protein S12 gene Rps12. Using strand-specific techniques, we find that transcription upstream of P1 originates from the DNA strand opposite Xist and represents the 3′ end of the antisense Tsix RNA. Thus, these data do not support the existence of a P0 promoter and suggest that mechanisms other than switching of functionally distinct promoters control the up-regulation of Xist.
In mammals, dosage compensation of X-linked genes is achieved by the transcriptional silencing of a single X chromosome during early female development (1). The Xist gene resides within the X inactivation center (Xic), a master control region for X inactivation, and is a current focus for understanding the early events that lead to X inactivation. Xist encodes a large untranslated RNA (2, 3), which is localized to the nucleus (4) and is required for X inactivation (5). Before differentiation, Xist is expressed at low levels from all X chromosomes in male and female cells (6–9). During differentiation, Xist RNA becomes abundantly expressed from the future inactive X in females and is silenced on future active female X and male X chromosomes. At this time, Xist RNA accumulates along and completely coats the inactive X in cis, an event that correlates with chromosome silencing. In the prevailing view, Xist up-regulation results from increased RNA half-life at the onset of cellular differentiation (8, 9).
Johnston et al. (10) recently proposed that a developmentally regulated Xist promoter switch is responsible for this change in RNA half-life. The study suggests that two functionally distinct promoters are present within the Xist gene. The P1 (and P2) promoter is used in differentiated female cells for production of a stable transcript that coats the inactive X chromosome. According to the hypothesis, a second promoter, P0, lies 6.6 kilobases (kb) upstream of P1 and produces unstable Xist transcripts in undifferentiated cells that have not undergone X inactivation. The model proposes that a switch from P0 to P1 during cell differentiation occurs on a single X chromosome in female cells, resulting in the production of stable Xist transcripts and initiation of X inactivation in cis.
The model makes several testable predictions. First, if the P0 promoter is responsible for Xist transcription in undifferentiated cells, deleting the P0 promoter would lead to loss of Xist expression. Second, Xist expression from P1 would produce an intrinsically stable transcript. Third, the extended half-life of Xist RNA initiated from P1 would enable RNA accumulation in cis. We have tested these predictions by using a truncated Xist transgene lacking P0. We find that P0 is not required for Xist expression in undifferentiated cells. Furthermore, P1-directed transcription does not produce stable Xist transcripts or lead to accumulation of Xist RNA in undifferentiated cells. These results argue against functionally distinct promoters and prompted us to investigate the nature of the P0 transcript further. To our surprise, the reported location of P0 coincides with a ribosomal protein S12 pseudogene. Moreover, we find that transcription upstream of the Xist P1 promoter is antisense to Xist and represents the 3′ end of the Tsix gene. These data provide an alternative explanation for observations relating to P0 and suggest that promoter switching does not underlie the dynamic regulation of Xist at the onset of X inactivation.
Materials and Methods
All sequence information in this report is based on the conventional Xist numbering scheme (3). The Rps12 pseudogene (pS12X) is referenced as Rps12-ps1 in the mouse database.
Reverse Transcriptase (RT)–PCR.
For strand-specific RT-PCR, 10 μg of total cellular RNA isolated by RNAzol B reagent (Tel-Test, Friendswood, TX) was treated with 2 units of RNase-free DNase I at 37°C for 1 h. DNase was inactivated in the presence of EDTA at 70°C for 10 min. Samples were split in two for +RT and −RT reactions. Strand-specific primer (3 pmol) was annealed to 0.2–2 μg of total RNA at 70°C for 5 min and equilibrated to 50°C. First-strand cDNA was synthesized by using 200 units of Superscript II RT (GIBCO/BRL) for 1 h at 50°C. Reverse transcriptase was omitted for −RT controls. The enzyme was heat inactivated at 80°C for 30 min. The positions of the following primers are relative to the P1 promoter: 3s (−3,136 to −3,116), 3as (−2,963 to −2,981), 4s (−1,481 to −1,461), 4as (−1,223 to −1,241), 5s (−1,033 to −1,014), and 5as (−794 to −814); “s” denotes the sense primer, whereas “as” denotes the antisense. Primer pairs 2, 6, and 7 correspond to primer pairs 2, 4, and 6, respectively, as previously reported (11). CJ9, CJ10, CJ11, and CJ12 (10), Mix20 and Mx23b (12), and Rrm2A and Rrm2C (13) have been described. Sense RT-PCR at position 1 (see Fig. 5A) was performed by priming with CJ9 and amplifying with nested CJ11–CJ12, whereas antisense RT-PCR was performed by priming with CJ12 and amplifying with CJ9–CJ10. For all other positions, first-strand cDNA was synthesized with either sense or antisense primers (e.g., 3s) and then amplified with paired sense and antisense primers (e.g., 3s + 3as). Taq polymerase PCR was performed for 30–33 cycles with an annealing temperature of 52°C. Fractionated nuclear and cytoplasmic RNAs were prepared as described (14) and random primed to generate first-strand cDNA. RT-PCR of fractionated material was carried out to 30 cycles with primer pairs CJ9–CJ10 (data not shown) or CJ11–CJ12.
5′ End Mapping.
For 5′ rapid amplification of cDNA ends (RACE; Marathon kit, CLONTECH), double-stranded cDNA was synthesized from 8 μg of πJL3.9 embryonic stem (ES) total RNA by using primer Xist2 (positioned at +775 to +755 bp downstream of the Xist P1 promoter) with avian myeloblastosis virus RT at 42°C, and RACE linkers were ligated onto cDNA ends. First-round PCR products were generated by using a primer positioned at +378 to +355 bp downstream of the Xist P1 promoter and linker primer ap1, blotted to a nylon membrane and probed with a nested primer, Xist1, positioned at +275 to +295 bp downstream of the Xist P1 promoter, to confirm specificity (Fig. 1B). For additional confirmation, second-round PCR was carried out with nested primers ap2 and a primer positioned at +344 to +321 bp downstream of the Xist P1 promoter (data not shown).
Restriction Fragment Length Polymorphism (RFLP) Analysis of CJ11–CJ12 RT-PCR Products.
Total RNA (5 μg) isolated with Trizol (GIBCO/BRL) was DNase treated and heat inactivated as described above, precipitated, and annealed to 200 ng of random hexamer for 10 min at 70°C. Annealed RNA was split in two for +RT and −RT reactions, and first-strand cDNA was synthesized in a volume of 20 μl with 200 units Moloney murine leukemia virus-RT for 1 h at 37°C followed by incubation at 80°C for 10 min. cDNA (1 μl) was used as a template for PCR under the cycling protocol reported (10) with 100 ng each of CJ11 and CJ12 primer in a 25-μl reaction. After 30 cycles, 1 μl was diluted 25-fold into a mixture of fresh buffer, dNTPs, primers, and Taq polymerase and extended for one additional cycle (94°C for 1 min, 55°C for 45 s, and 72°C for 2 min) to minimize possible heteroduplex products arising from annealing of Rps12/pS12X PCR products. Extension reactions were precipitated with glycogen, washed in 70% (vol/vol) ethanol, and dried. Pellets were digested with 4 units of HinfI or TaqI (New England Biolabs) at 37°C or 65°C, respectively, and electrophoresed on a 2.5% agarose gel. Gels were transferred to positively charged nylon (Zetabind, Cuno) under alkaline conditions, hybridized to 32P-end-labeled oligonucleotide CJ10 overnight at 50°C, and washed in 6× SSC (0.15 M sodium chloride/0.015 M sodium citrate, pH 7)/0.1% SDS at 50°C by using standard protocols (14).
Northern Blotting.
Total RNA (10 μg) isolated from male and female fibroblast, male ES (J1), or female ES (EL16) cell lines was electrophoresed on a formaldehyde gel, transferred to positively charged nylon, and hybridized to a pS12X probe by using standard protocols (14). The pS12X probe was generated by PCR of genomic DNA with primers CJ9 and CJ12, followed by random priming with 32P-radiolabel.
Results
P0 Is Not Required for Xist Expression in Undifferentiated Cells.
The dynamic regulation of Xist expression is recapitulated by mouse ES cells during differentiation (5, 15), and many steps of this regulation can be reenacted on mouse autosomes carrying Xist transgenes (16–18). To test the predictions of the promoter-switch hypothesis, we examined effects of deleting P0 on an autosomal Xist transgene in ES cells. We had previously isolated a P1 clone, πJL3, which contains 80 kb of Xic sequence including an intact Xist gene, 730 bp of sequence upstream of P1, and 60 kb of sequence downstream of Xist (17). Thus, the transgene lacks P0 but contains the 400-bp P1 promoter shown by several groups to contain the minimal Xist promoter for expression in somatic and ES cells (19, 20). We had shown that transgenic ES cell lines carrying a high copy number insertion of πJL3 could express Xist despite lacking P0 sequence.
Because a recent study revealed that transgenic Xist expression depends on transgene copy number (21), we wished in this study to verify the ability of πJL3 to express Xist in lower copy ES cell lines. πJL3.1 and πJL3.9 carry one to two and four to five copies, respectively. By using strand-specific probes, RNA FISH revealed Xist expression from both the endogenous and ectopic loci in undifferentiated πJL3.1 and πJL3.9 cells (Fig. 1A), consistent with the prior observation that Xist was expressed from higher copy transgenic lines πJL3.6, πJL3.8, and πJL3.10 (17). Thus, in undifferentiated cells, P0 sequences were dispensable for Xist expression on a transgene array regardless of copy number. RACE (5′) suggested three potential transcriptional start sites in transgenic cells (Fig. 1B): one corresponding to initiation at P1 (360 bp band), another indicating initiation ≈200 bp upstream of P1, and the last suggesting yet another start site ≈200 bp downstream of P1. The observed use of additional promoters near P1 is consistent with previous reports of multiple start sites in close proximity to the P1 promoter (3). For purposes of discussion, we refer to this collection of start sites as “P1.” These results also indicate that the P1 promoter is used by undifferentiated cells, contrary to the first prediction of the P0 hypothesis.
Transcripts Initiated at the P1 Promoter Are Not Intrinsically Stable and Do Not Accumulate in cis.
The finding that Xist can be expressed from P1 in undifferentiated cells provided the opportunity to test whether P1 initiation led to increased Xist RNA half-life. The promoter-switch hypothesis predicts that P1 transcripts would have a half-life comparable to that of Xist RNA in somatic female cells. We treated normal and transgenic cells with actinomycin D and analyzed Xist expression at different time points (Fig. 2A). In contrast to the prediction of the promoter-switch hypothesis, we found that the transgenic RNA was as unstable as Xist RNA in normal male and female ES cells. This result argued that transcription from P1 (and from additional promoters located within 200 bp of P1) did not yield an intrinsically stable RNA. The result argued further that neither P0 nor any sequence upstream of −730 bp (transgene boundary) is required for production of unstable Xist transcripts.
A corollary of the RNA stabilization hypothesis and the promoter-switch hypothesis is that RNA stabilization leads to coating of the chromosome in cis. To test whether the P1-initiated transcript could coat the chromosome, we performed RNA FISH on metaphase chromosomes of undifferentiated and differentiated πJL3.1 and πJL3.9 ES cells (Fig. 2B). We found that the P1-initiated RNA did not coat chromosomes of either undifferentiated ES cells or their differentiating derivatives up to day 11 (embryoid bodies). Taken together, these observations showed that P0 sequences are required neither for Xist expression in ES cells nor for production of unstable Xist transcripts.
The Transcriptional Boundary at P0 Results from a Ribosomal Protein S12 Pseudogene (pS12X) and Not an Xist Promoter.
The existence of a promoter at P0 was inferred from RT-PCR data indicating positive reactions downstream of primer CJ12 and negative reactions upstream (10). The promoter was reported to lie between bp −6,590 and −6,725 upstream of P1 (see Fig. 5A). In the course of our analysis, we were surprised to discover that this region (bp −6,635 to −6,136) bears striking homology (94% identity over 500 bp) to mouse ribosomal protein S12 (Rps12) cDNA (Figs. 3A and 5A; ref. 22). This sequence has many features of a processed pseudogene (23): It contains multiple nucleotide substitutions and insertions, is punctuated by stop codons in all three frames, is flanked by direct repeats, and carries a 3′ poly(A) tract (Fig. 3A). We named this pseudogene pS12X (Rps12-ps1 in the mouse database). As a processed pseudogene and because of data shown below, this sequence is unlikely to be transcribed. Additionally, this sequence is not conserved at the human XIC as determined by dot plot analysis (data not shown).
Of note, primers used to define the P0 promoter lie within the pseudogene and are either identical (CJ10, CJ11) or nearly identical (CJ12) to the autosomally expressed Rps12 gene (Fig. 3A). CJ9 lies outside of Rps12 expressed sequence tags but yields amplification similar to that of CJ11–CJ12 primer pairs (data not shown). Because of the primers’ nearly perfect identity to Rps12 sequences, we considered the possibility that the assignment of the P0 transcriptional boundary might be an artifact caused by cross-amplification of Rps12 RNA. We found that RT-PCR with CJ11–CJ12 and CJ9–CJ10 primer pairs gave specific amplification in both ES cells and adult somatic tissue, including liver, brain, and fibroblasts (Fig. 3B and data not shown). Thus, in our hands, transcripts defined by these primers are not specific to ES cells but are ubiquitously expressed, a result that differs from the ES-specific expression profile reported previously (10). This finding suggested to us that P0 transcription may indeed reflect Rps12 rather than Xist expression.
This notion is supported by the following observations. First, Northern analysis with a pS12X genomic probe (PCR product of CJ9–CJ12) detected a band of 400–600 bases, consistent with the 470-base transcript reported for Rps12 mRNA (Fig. 3C; GenBank accession no. X15962). This mRNA was expressed in both ES and somatic cells and in both XX and XY cells. Second, we reasoned that, if CJ11–CJ12 amplification reflected Xist expression, the RT-PCR product would be found only in nuclear RNA fractions and not in the cytoplasmic fraction. However, RT-PCR analysis of fractionated nuclear and cytoplasmic RNAs revealed that CJ11–CJ12 products were present in both nuclear and cytoplasmic compartments (Fig. 4A). Because Xist was exclusively nuclear (Fig. 4A; refs. 2 and 3), this observation argued that Xist and the CJ11–CJ12 product cannot be identical. Because a fraction of the CJ11–CJ12 product was also found in the nucleus, it was formally possible that CJ11–CJ12 amplified both Xist and Rps12 RNA. To rule out this possibility, we performed RFLP analysis of CJ11–CJ12 RT-PCR products. In this assay, Rps12 and the Xic-linked pS12X sequence could be distinguished by RFLPs in TaqI and HinfI (Fig. 4B). Our analysis indicated that CJ11–CJ12 exclusively amplified autosomal Rps12 RNA (Fig. 4C). This result held true for all lines tested and for both HinfI and TaqI RFLPs. By mixing known amounts of Rps12 and pS12X products, we determined that this assay could detect pS12X RNA if it were as rare as 0.1 to 0.01% of total amplified product (Fig. 4D). Thus, this sensitive PCR assay failed to detect the Xist-linked pS12X product (P0 RNA). The Rps12 origin indicated by the RFLP profiles was then confirmed by direct sequencing, revealing complete sequence identity of the CJ11–CJ12 RT-PCR product with Rps12 cDNA (data not shown). We conclude that the P0 transcriptional boundary was indeed an artifact of PCR cross-amplification caused by autosomally expressed Rps12 RNA.
Transcripts Upstream of the P1 Promoter in Undifferentiated Cells Represent the 3′ End of Tsix RNA.
In light of the above conclusions, we sought to address the origin of transcription in the region upstream of P1. Given that Tsix antisense RNA crosses this region (11), we asked how much of upstream transcription in undifferentiated cells could be attributed to Tsix. Relevant to this point, much of the prior work (10) used double-stranded Xist probes and randomly primed PCR and therefore did not distinguish between sense and antisense transcription. In this study, we carried out strand-specific RT-PCR in undifferentiated cells at various intervals within a 12-kb region surrounding P1 (Fig. 5A). We found that transcription upstream of P1 was exclusively in the antisense orientation (Fig. 5B), consistent with previous analysis (11). By including more PCR cycles, weak bands in the sense orientation were detectable at position 6 (Fig. 5B). The idea of minor transcriptional start sites in the immediate vicinity of P1 agrees with 5′ RACE analysis of πJL3 transgenic lines (Fig. 1B) and with previous analysis (3). Sense transcription was never observed upstream of position 6. We conclude that transcription upstream of P1 can be accounted for by the 3′ end of Tsix. These results argue further against a functionally distinct Xist isoform in undifferentiated ES cells.
Discussion
To test the promoter-switch hypothesis, we have examined the effects of deleting P0 sequences on a Xist transgene and found that deleting P0 did not abolish Xist expression in cis in undifferentiated transgenic cells. Xist expression could be initiated from the P1 promoter and other minor promoters within 200 bp of P1 in undifferentiated cells. This finding is consistent with previous reports that the minimal promoter for Xist expression in ES and somatic cells is contained with a 400-bp region immediately upstream of the P1 promoter (19, 20, 24). These results indicate that the P0 region is not required for Xist transcription on a transgene array in undifferentiated ES cells. We also found that these P1-initiated Xist transcripts were not intrinsically more stable, contrary to the predictions of the promoter-switch hypothesis. Therefore, we believe that P0 sequences are required neither for expression nor for rapid turnover of Xist RNA in ES cells.
Further testing revealed that many observations relating to P0 can be accounted for by Tsix and Rps12 expression. The data presented herein did not substantiate the existence of an ES-specific promoter at P0. Although amplification with the P0 primer pairs, CJ9–CJ10 and CJ11–CJ12, was previously reported to be ES-specific, we have found that RT-PCR products were present in both ES and adult cells. We believe that the transcriptional boundary at P0 is an artifact caused by cross-amplification of a coincidental pseudogene for the highly expressed autosomal Rps12 gene, a conclusion supported by the following findings. First, Northern analysis with the pS12X pseudogene as a probe indicated robust expression in all cell types tested. Secondly, CJ9–CJ10 and CJ11–CJ12 primers gave amplification in both ES and somatic cells. Third, CJ11–CJ12 products were found in both cytoplasmic and nuclear compartments, whereas Xist RNA was found only within the nucleus. Fourth, a sensitive RFLP analysis of CJ11–CJ12 amplified products failed to detect any Xic-derived transcription. Because pS12X is not conserved at the human XIC (data not shown), the pseudogene sequence itself seems unlikely to play a role in Xist regulation.
An additional complication for the promoter-switch hypothesis arises from the presence of antisense (Tsix) transcription upstream of P1. Our data suggest that transcription upstream of P1 is only of antisense origin. Relevant to this finding, the original mapping of P0 was carried out exclusively by RT-PCR and largely without regard to transcript orientation (10). Strand-specific RNA FISH was performed in one experiment and was reported to show expression only in the sense (Xist) orientation at positions −3 kb and −1 kb upstream of P1. We cannot explain this apparent discrepancy. However, our results are consistent with the original mapping of Tsix relative to Xist (11) and with a subsequent study showing exclusive antisense transcription in the region upstream of P1 (25). Furthermore, a recent promoter knockout of Tsix showed that, in the absence of antisense RNA upstream of P0, no transcription was detectable in the P0–P1 region with either sense-specific or double-stranded RNA FISH probes (26). Finally, substantiation of a 5′ end at P0 would require nuclease protection, primer extension, or 5′ RACE. We have been unable to recover the 5′ end of any potential Xist isoform in the vicinity of P0 by using 5′ RACE or primer extension (data not shown).
If P0 sequences are not required for Xist regulation, do other upstream sequences play a role in X inactivation? A prior study did suggest the presence of at least one element in the 30-kb region immediately upstream of P1 (17). ES cells carrying the πJL3 transgene could express Xist while they were in the undifferentiated state, but differentiation led to Xist repression in five independently derived cell lines. This result contrasts with ES cell lines carrying Xist transgenes containing an additional 30 kb of sequence upstream of P1, all of which enabled Xist up-regulation and RNA accumulation in cis upon cell differentiation. The data therefore point to the existence of a positive regulatory element upstream that potentiates high-level Xist expression. Importantly, this element cannot be an ES cell-specific element such as the proposed P0 promoter, because prior data argued that this element acts as a potentiator in somatic and not ES cells (17).
We began this study by testing the predictions of the promoter-switch hypothesis and have found no evidence for functionally distinct promoters upstream of P1. Our conclusions have technical and mechanistic implications for the study of X inactivation. First, this study underscores the importance of using strand-specific probes for Xic analysis. Indeed, because Xist expression has historically been examined with double-stranded probes, this study urges reconsideration of some conventionally held wisdom regarding Xist. Other properties previously ascribed to Xist may actually belong to Tsix. Second, although we remain open to the idea that a promoter other than P0 regulates Xist RNA stability, no data presented here or anywhere else support such a mechanism. Although alternative Xist promoters might indeed exist, the available genetic and biochemical evidence makes other mechanisms equally plausible. Because knockout analysis shows that Tsix regulates Xist expression in cis, one possibility is that the antisense RNA alters Xist RNA half-life, perhaps by RNA duplex formation or by recruitment of other regulatory factors. It is also possible that control of Xist up-regulation resides in elements not yet defined. We hope that the point of view presented herein will instigate a search for additional elements and stimulate new ideas on regulatory mechanisms.
Acknowledgments
We thank Lance Davidow for dot plot analysis of murine and human Xic sequences upstream of P1 and Jason Conaty, Yuya Ogawa, Dena E. Cohen, Tracey Budzinski, and James E. Kirby for discussion and critical reading of the manuscript. D.W. was supported by National Research Service Award F32-GM19846A01, and N.S. was supported by a Howard Hughes Medical Institute Predoctoral Fellowship. This study was funded by National Institutes of Health Grant RO1-GM58839 and a Hoechst Award granted to J.T.L.
Abbreviations
- kb
kilobase
- RT
reverse transcriptase
- RACE
rapid amplification of cDNA ends
- ES
embryonic stem
- RFLP
restriction fragment length polymorphism
Footnotes
This paper was submitted directly (Track II) to the PNAS office.
References
- 1.Lyon M F. Nature (London) 1961;190:372–373. doi: 10.1038/190372a0. [DOI] [PubMed] [Google Scholar]
- 2.Brown C J, Hendrich B D, Rupert J L, Lafreniere R G, Xing Y, Lawrence J, Willard H F. Cell. 1992;71:527–542. doi: 10.1016/0092-8674(92)90520-m. [DOI] [PubMed] [Google Scholar]
- 3.Brockdorff N, Ashworth A, Kay G F, McCabe V M, Norris D P, Cooper P J, Swift S, Rastan S. Cell. 1992;71:515–526. doi: 10.1016/0092-8674(92)90519-i. [DOI] [PubMed] [Google Scholar]
- 4.Clemson C M, McNeil J A, Willard H, Lawrence J B. J Cell Biol. 1996;132:259–275. doi: 10.1083/jcb.132.3.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Penny G D, Kay G F, Sheardown S A, Rastan S, Brockdorff N. Nature (London) 1996;379:131–137. doi: 10.1038/379131a0. [DOI] [PubMed] [Google Scholar]
- 6.Tai H H, Gordon J, McBurney M W. Somatic Cell Mol Genet. 1994;20:171–182. doi: 10.1007/BF02254758. [DOI] [PubMed] [Google Scholar]
- 7.Beard C, Li E, Jaenisch R. Genes Dev. 1995;9:2325–2334. doi: 10.1101/gad.9.19.2325. [DOI] [PubMed] [Google Scholar]
- 8.Panning B, Dausman J, Jaenisch R. Cell. 1997;90:907–916. doi: 10.1016/s0092-8674(00)80355-4. [DOI] [PubMed] [Google Scholar]
- 9.Sheardown S A, Duthie S M, Johnston C M, Newall A E T, Formstone E J, Arkell R M, Nesterova T B, Alghisi G-C, Rastan S, Brockdorff N. Cell. 1997;91:99–107. doi: 10.1016/s0092-8674(01)80012-x. [DOI] [PubMed] [Google Scholar]
- 10.Johnston C M, Nesterova T B, Formstone E J, Newall A E T, Duthie S M, Sheardown S A, Brockdorff N. Cell. 1998;94:809–817. doi: 10.1016/s0092-8674(00)81739-0. [DOI] [PubMed] [Google Scholar]
- 11.Lee J T, Davidow L S, Warshawsky D. Nat Genet. 1999;21:400–404. doi: 10.1038/7734. [DOI] [PubMed] [Google Scholar]
- 12.Kay G F, Penny G D, Patel D, Ashworth A, Brockdorff N, Rastan S. Cell. 1993;72:171–182. doi: 10.1016/0092-8674(93)90658-d. [DOI] [PubMed] [Google Scholar]
- 13.Lee J T, Jaenisch R. Nature (London) 1997;386:275–279. doi: 10.1038/386275a0. [DOI] [PubMed] [Google Scholar]
- 14.Ausubel F M, Brent R, Kingston R E, Moore D D, Seidman J G, Smith J A, Struhl K. Current Protocols in Molecular Biology. New York: Wiley; 1994. [Google Scholar]
- 15.Rastan S, Robertson E J. J Embryol Exp Morphol. 1985;90:379–388. [PubMed] [Google Scholar]
- 16.Lee J T, Strauss W M, Dausman J A, Jaenisch R. Cell. 1996;86:83–94. doi: 10.1016/s0092-8674(00)80079-3. [DOI] [PubMed] [Google Scholar]
- 17.Lee J T, Lu N F, Han Y. Proc Natl Acad Sci USA. 1999;96:3836–3841. doi: 10.1073/pnas.96.7.3836. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Herzing L B K, Romer J T, Horn J M, Ashworth A. Nature (London) 1997;386:272–275. doi: 10.1038/386272a0. [DOI] [PubMed] [Google Scholar]
- 19.Hendrich B D, Plenge R M, Willard H F. Nucleic Acids Res. 1997;25:2661–2671. doi: 10.1093/nar/25.13.2661. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Sheardown S A, Newall A E T, Norris D P, Rastan S, Brockdorff N. Gene. 1997;203:159–168. doi: 10.1016/s0378-1119(97)00507-6. [DOI] [PubMed] [Google Scholar]
- 21.Heard E, Mongelard F, Arnaud D, Avner P. Mol Cell Biol. 1999;19:3156–3166. doi: 10.1128/mcb.19.4.3156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ayane M, Nielsen P, Kohler G. Nucleic Acids Res. 1989;17:6722. doi: 10.1093/nar/17.16.6722. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Vanin E F. Annu Rev Genet. 1985;19:253–272. doi: 10.1146/annurev.ge.19.120185.001345. [DOI] [PubMed] [Google Scholar]
- 24.Pillet N, Bonny C, Schorderet D F. Proc Natl Acad Sci USA. 1995;92:12515–12519. doi: 10.1073/pnas.92.26.12515. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Mise N, Goto Y, Nakajima N, Takagi N. Biochem Biophys Res Commun. 1999;258:537–541. doi: 10.1006/bbrc.1999.0681. [DOI] [PubMed] [Google Scholar]
- 26.Lee J T, Lu N. Cell. 1999;99:47–57. doi: 10.1016/s0092-8674(00)80061-6. [DOI] [PubMed] [Google Scholar]
- 27.Rougeulle C, Avner P. Mamm Genome. 1996;7:606–607. doi: 10.1007/s003359900179. [DOI] [PubMed] [Google Scholar]